Vorapaxar: The Current Role and Future Directions of a Novel Protease-Activated Receptor Antagonist for Risk Reduction in Atherosclerotic Disease

INTRODUCTION: Despite the current standard of care, patients with cardiovascular disease remain at a high risk for recurrent events. Inhibition of thrombin-mediated platelet activation through protease-activated receptor-1 antagonism may provide reductions in atherosclerotic disease beyond those ach...

Descripción completa

Detalles Bibliográficos
Autores principales: Gryka, Rebecca J., Buckley, Leo F., Anderson, Sarah M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2017
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5318326/
https://www.ncbi.nlm.nih.gov/pubmed/28063023
http://dx.doi.org/10.1007/s40268-016-0158-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5318326/
https://www.ncbi.nlm.nih.gov/pubmed/28063023
http://dx.doi.org/10.1007/s40268-016-0158-4

Ejemplares similares